<DOC>
	<DOCNO>NCT01049490</DOCNO>
	<brief_summary>Primary objective : To evaluate safety immunogenicity low-dose ID S-OIV H1N1 vaccine deliver via novel microneedle device ( MicronJet600 ) compare full-dose standard IM injection . Hypothesis : Low dose ( 20 % ) intradermal ( ID ) S-OIV H1N1 vaccine deliver via novel microneedle device ( MicronJet600 ) equally effective full-dose standard intramuscular ( IM ) vaccine .</brief_summary>
	<brief_title>Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device</brief_title>
	<detailed_description>This prospective randomise , single-blinded trial Queen Mary Hospital . We aim recruit 200 subject [ minimum 80 subject per age group ( 21-65 chronic disease age 65+ ) ] would qualify Hospital Authority ( HA ) / Centre Health Protection ( CHP ) Mass Vaccination Program S-OIV H1N1 . These patient include elderly age 65 adult patient age 21 chronic illness . Subjects randomly assign receive either full-dose ( 1 dose ) standard Panenza vaccine day 0 ( 15ug non-adjuvanted monovalent influenza A ( H1N1 ) 2009 vaccine ) deliver intramuscularly use conventional needle ( IM group ) low-dose ( 1 dose ) intradermal injection Panenza vaccine day 0 ( 3ug non-adjuvanted monovalent influenza A ( H1N1 ) 2009 vaccine ) deliver MicronJet600 ( ID group ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All participant qualify HA/ CHP Mass Vaccination Program SOIV H1N1 state : include elderly age 65 adult patient age 21 chronic illness include hypertension , diabetes mellitus , ischemic heart disease , cerebrovascular disease , thyroid disease chronic renal failure . All patient give write informed consent . Subjects must available complete study comply study procedure . Willingness allow serum sample store beyond study period , potential additional future test good characterize immune response . Clinically significant immunerelated disease , significant recent comorbidities pregnant volunteer . Inability comprehend follow require study procedure . History illness might interfere result study pose additional risk subject due participation study Have receive SOIV H1N1 vaccination . Have recent ( start May 2009 ) history ( document , confirm suspect ) flulike disease ) . Have know allergy egg component Study Vaccines ( include gelatin , formaldehyde , octoxinol , thimerosal , chicken protein ) , history anaphylaxis , serious vaccine reaction , excipients . Have positive urine serum pregnancy test within 24 hour prior vaccination , woman breastfeed . Female childbearing potential , use acceptable contraceptive method least 2 month prior study entry plan use acceptable birth control .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Intradermal vaccination , H1N1 , microneedle</keyword>
</DOC>